<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05014555</url>
  </required_header>
  <id_info>
    <org_study_id>CNTO1275IBD4005</org_study_id>
    <nct_id>NCT05014555</nct_id>
  </id_info>
  <brief_title>Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease</brief_title>
  <official_title>Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GI Alliance</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GI Alliance</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the impact of systemic immunosuppression on sustained&#xD;
      antibody COVID-19 concentrations in patients with IBD who received a COVID-19 vaccine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the immunogenicity of the COVID-19 vaccines by measuring geometric mean titers (GMT) of SARS-CoV-2 antibody concentrations, and quantitative assays to evaluate RBD-binding IgG levels</measure>
    <time_frame>6 and 12 months after second dose of the COVID-19 vaccine, with primary outcome being sustained antibody concentrations at 12 months</time_frame>
    <description>Evaluation of the immunogenicity of the COVID-19 vaccines by measuring geometric mean titers (GMT) of SARS-CoV-2 antibody concentrations at 6 and 12 months after the 2nd dose of the vaccine in patients with IB. Quantitative assays will be used to evaluate RBD-binding IgG levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained cell-mediated immunity against Covid-spike proteins will be evaluated using IFN-ϒ ELISpot, which detects both CD4 and CD8 T cell effectors.</measure>
    <time_frame>6 and 12 months after second dose of the COVID-19 vaccine</time_frame>
    <description>Evaluation of sustained cell mediated immunity against Covid-spike proteins. IFN-ϒ ELISpot, which detects both CD4 and CD8 T cell effectors, will be used to detect T-cell immunity to the Covid-spike protein or peptides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the persistence of memory B cell using memory B cell analysis.</measure>
    <time_frame>6 and 12 months after second dose of the COVID-19 vaccine</time_frame>
    <description>Evaluation of the persistence of memory B cell in approximately one-third of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained antibody concentration evaluating spike protein and receptor binding</measure>
    <time_frame>6 and 12 months after second dose of the COVID-19 vaccine</time_frame>
    <description>The NIH ELISA assay will be used to evaluate change in S and RBD (IgG and IgM) antibody titers.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Group A Non-biologic Group</arm_group_label>
    <description>Participants on treatment regimen of mesalamine monotherapy or thiopurine monotherapy, or corticosteroids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B Anti-TNF Group</arm_group_label>
    <description>Participants on treatment regimen of maintenance montherapy of infliximab (at least 8 every 8 weeks), golilumamb (at least monthly), adalimumab (at least every 2 weeks), or certolizumab (at least monthly), or combination therapy of anti-TNF therapy as described above along with either 15mg of methotrexate or azathiprine at least 1.0mg/kg or 6MP 0.5mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C Ustekinumab Group</arm_group_label>
    <description>Participants on treatment regimen of ustekinumab monotherapy or combination therapy with methotrexate or azathioprine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D Vedolizumab Group</arm_group_label>
    <description>Participants on vedolizumab monotherapy or combination therapy with methotrexate or azathioprine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 Vaccine</intervention_name>
    <description>Two-dose mRNA COVID-19 vaccine per standard of care</description>
    <arm_group_label>Group A Non-biologic Group</arm_group_label>
    <arm_group_label>Group B Anti-TNF Group</arm_group_label>
    <arm_group_label>Group C Ustekinumab Group</arm_group_label>
    <arm_group_label>Group D Vedolizumab Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Inflammatory bowel disease patients, Gastroenterology practice&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is between the ages of 18-85 years, inclusive.&#xD;
&#xD;
          -  Patient has a history of ulcerative colitis (UC) or Crohn's disease diagnosed by&#xD;
             standard clinical, radiographic, endoscopic, and histopathologic criteria.&#xD;
&#xD;
          -  On one of the following treatment regimens for at least three months at the time of&#xD;
             immunization and continued same therapy at the time of recruitment. Should be on&#xD;
             stable doses defined as: Group A should have taken a dose of medication within the&#xD;
             past week; Group B infliximab within the previous 8 weeks, golilumab within the&#xD;
             previous 4 weeks, adalilumab within the previous 2 weeks, or certolizumab within the&#xD;
             previous 4 weeks; Those on combination therapy in group B will have taken azathioprine&#xD;
             or methotrexate within the past week. Group C ustekinumab at least within the previous&#xD;
             4 weeks. Those on combination therapy in group C will have taken azathioprine or&#xD;
             methotrexate within the past week; Group D vedolizumab at least within the previous 4&#xD;
             weeks. Those on combination therapy in group D will have taken azathioprine or&#xD;
             methotrexate within the past week.&#xD;
&#xD;
               -  Group A non-biologic group: mesalamine monotherapy or thiopurine monotherapy&#xD;
&#xD;
               -  Group B: Anti-TNF Therapy Group: on maintenance therapy infliximab (at least&#xD;
                  5mg/kg every 8 weeks), golimumab (at least monthly), adalimumab (at least every 2&#xD;
                  weeks), or certolizumab (at least monthly). Combination Therapy Anti-TNF&#xD;
                  Combination Therapy Group: on anti-TNF therapy as described above along with&#xD;
                  either 15mg of methotrexate or azathioprine at least 1.0mg/kg or 6MP 0.5mg/kg at&#xD;
                  least 40% of the group.&#xD;
&#xD;
                    -  Approximately (40-50% of the group) will be combination therapy.&#xD;
&#xD;
               -  Group C: Ustekinumab on either ustekinumab monotherapy or combination therapy&#xD;
                  with methotrexate or azathioprine.&#xD;
&#xD;
               -  Group D: Vedolizumab Therapy Group: Vedolizumab Therapy: on either vedolizumab&#xD;
                  monotherapy or combination therapy with methotrexate or azathioprine&#xD;
&#xD;
          -  Patient received a two-dose mRNA COVID-19 vaccine per standard of care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous COVID-19 infection&#xD;
&#xD;
          -  Patient cannot or will not provide written informed consent.&#xD;
&#xD;
          -  Unable to provide appropriate informed consent due to being illiterate or impairment&#xD;
             in decision-making capacity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Ritter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GI Alliance</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauri Befus</last_name>
    <phone>214-924-5996</phone>
    <email>Lauri.Befus@gialliance.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jackie Ward</last_name>
    <phone>817-310-4421</phone>
    <email>Jacklyn.Ward@gialliance.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville, FL</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Francis A Farraye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GI Alliance</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lauri Befus</last_name>
      <phone>214-924-5996</phone>
      <email>Lauri.Befus@gialliance.com</email>
    </contact>
    <contact_backup>
      <last_name>Dana Reed-Alexander</last_name>
      <phone>225-927-1190</phone>
      <phone_ext>7850</phone_ext>
      <email>Dana.Reed-alexander@gialliance.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GI Alliance</name>
      <address>
        <city>Cedar Park</city>
        <state>Texas</state>
        <zip>78613</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lauri Befus</last_name>
      <phone>214-924-5996</phone>
      <email>Lauri.Befus@gialliance.com</email>
    </contact>
    <contact_backup>
      <last_name>Jocelyn Largent</last_name>
      <phone>512-861-3596</phone>
      <phone_ext>6088</phone_ext>
      <email>jocelyn.largent@gialliance.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GI Alliance</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lauri Befus</last_name>
      <phone>214-924-5996</phone>
      <email>Lauri.Befus@gialliance.com</email>
    </contact>
    <contact_backup>
      <last_name>Weam Ali</last_name>
      <phone>832-618-6852</phone>
      <email>Weam.Ali@gialliance.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53726</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Freddy Caldera, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 13, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Immediately following publication.</ipd_time_frame>
    <ipd_access_criteria>With researchers who provide a methodically sound proposal, to achieve aims in the approved proposal. Proposals should be directed to Tim.Ritter@GIAlliance.com.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

